AU2012314501B2 - Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists - Google Patents

Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists Download PDF

Info

Publication number
AU2012314501B2
AU2012314501B2 AU2012314501A AU2012314501A AU2012314501B2 AU 2012314501 B2 AU2012314501 B2 AU 2012314501B2 AU 2012314501 A AU2012314501 A AU 2012314501A AU 2012314501 A AU2012314501 A AU 2012314501A AU 2012314501 B2 AU2012314501 B2 AU 2012314501B2
Authority
AU
Australia
Prior art keywords
group
cpd
triazolo
chloro
pyridazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012314501A
Other languages
English (en)
Other versions
AU2012314501A1 (en
Inventor
Maryline; Bourotte
Jean-François DELHOMEL
Mathieu DUBERNET
Marie-Helene Gouy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Publication of AU2012314501A1 publication Critical patent/AU2012314501A1/en
Application granted granted Critical
Publication of AU2012314501B2 publication Critical patent/AU2012314501B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
AU2012314501A 2011-09-27 2012-09-27 Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists Ceased AU2012314501B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11306234.3 2011-09-27
EP11306234 2011-09-27
EP12163795 2012-04-11
EP12163795.3 2012-04-11
PCT/EP2012/069014 WO2013045519A1 (en) 2011-09-27 2012-09-27 Derivatives of 6-substituted triazolopyridazines as rev-erb agonists

Publications (2)

Publication Number Publication Date
AU2012314501A1 AU2012314501A1 (en) 2014-05-15
AU2012314501B2 true AU2012314501B2 (en) 2017-02-16

Family

ID=46934586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012314501A Ceased AU2012314501B2 (en) 2011-09-27 2012-09-27 Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists

Country Status (12)

Country Link
US (2) US9586963B2 (enExample)
EP (1) EP2760866B1 (enExample)
JP (1) JP6042438B2 (enExample)
CN (1) CN104024259B (enExample)
AU (1) AU2012314501B2 (enExample)
BR (1) BR112014006924B1 (enExample)
CA (1) CA2848518C (enExample)
EA (1) EA029834B1 (enExample)
IL (1) IL231501B (enExample)
MX (1) MX356683B (enExample)
WO (1) WO2013045519A1 (enExample)
ZA (1) ZA201402975B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1208681A1 (en) * 2012-06-12 2016-03-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
US9872851B2 (en) * 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
ITTO20130816A1 (it) * 2013-10-09 2015-04-10 Fond Istituto Italiano Di Tecnologia Antagonisti di rev-erb diarilalchilaminici e loro uso come farmaci
CN105596336B (zh) * 2016-01-18 2018-05-22 暨南大学 化合物sr8278在制备治疗i型糖尿病角膜病变药物中的应用
CA3281817A1 (en) 2016-11-28 2026-03-02 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018098491A1 (en) * 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018148531A1 (en) * 2017-02-10 2018-08-16 Case Western Reseve University Compositions and methods of treating cardiac hypertrophy and heart failure
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN111712492B (zh) * 2017-12-19 2024-05-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸三唑唑类
IL309843B2 (en) 2018-05-30 2026-05-01 Praxis Prec Medicines Inc History of [4,2,1]triazolo[3,4-a]pyridines and their use as sodium ion channel modulators
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
JP2023503343A (ja) 2019-11-26 2023-01-27 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
PE20221280A1 (es) 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
AR121846A1 (es) * 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
EP4228632A4 (en) * 2020-10-16 2025-02-19 Saint Louis University Rev-erb agonists
KR20250005348A (ko) 2022-04-26 2025-01-09 프락시스 프리시젼 메디신즈, 인크. 신경 장애의 치료
CN114907333B (zh) * 2022-05-11 2023-07-04 中国人民解放军军事科学院军事医学研究院 环丙甲酰胺衍生物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms
WO2010089507A1 (fr) * 2009-02-06 2010-08-12 Sanofi-Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5233583B2 (enExample) * 1972-06-15 1977-08-29
JPS603080B2 (ja) * 1976-08-10 1985-01-25 三菱化学株式会社 Ｓ―トリアゾロ〔３，４ ―α〕〔５，６，７，８〕テトラヒドロ フタラジン類
JPS54128595A (en) 1978-03-29 1979-10-05 Nippon Nohyaku Co Ltd Triazolopyridazine compound
DE3222342A1 (de) 1982-06-14 1983-12-15 Hoechst Ag, 6230 Frankfurt 6-aryl-1,2,4-triazolo (4,3-b) pyridazin-3-carbaminate, ihre herstellung und sie enthaltende arzneimittel
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
FR2780512B1 (fr) 1998-06-25 2003-10-17 Lipha Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique
FR2834996B1 (fr) 2002-01-18 2004-12-03 Genfit S A Methode d'identification de substances capables de moduler la differenciation adipocytaire
WO2004053124A1 (ja) 2002-12-06 2004-06-24 Shionogi & Co., Ltd. 糖尿病治療剤又は予防剤のスクリーニング方法
AU2003297161B8 (en) * 2002-12-18 2011-03-31 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
WO2005076004A1 (en) 2004-02-10 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human nuclear receptor nr1d1 (nr1d1)
EA016527B1 (ru) 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Триазолопиридазиновые модуляторы протеинкиназ
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8642583B2 (en) * 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
JP5321197B2 (ja) * 2009-03-31 2013-10-23 Ｄｉｃ株式会社 含フッ素ラジカル重合性ブロック共重合体、それを用いた活性エネルギー線硬化型樹脂組成物及び含フッ素ラジカル重合性ブロック共重合体の製造方法
HUE034911T2 (hu) 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
WO2011022619A1 (en) 2009-08-20 2011-02-24 Glaxo Group Limited TREATING INFLAMMATORY DISEASES BY ADMINISTRATION OF REV-ERB α LIGANDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms
WO2010089507A1 (fr) * 2009-02-06 2010-08-12 Sanofi-Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAPLUS Accession Number 2009:846106 *

Also Published As

Publication number Publication date
HK1200448A1 (en) 2015-08-07
ZA201402975B (en) 2015-04-29
US20170296548A1 (en) 2017-10-19
EA201400392A1 (ru) 2014-09-30
EA029834B1 (ru) 2018-05-31
MX2014003637A (es) 2014-09-22
JP2014527996A (ja) 2014-10-23
BR112014006924A8 (pt) 2018-01-09
BR112014006924B1 (pt) 2020-10-06
AU2012314501A1 (en) 2014-05-15
CA2848518C (en) 2019-06-18
US20150038503A1 (en) 2015-02-05
IL231501B (en) 2018-05-31
EP2760866A1 (en) 2014-08-06
US10799510B2 (en) 2020-10-13
EP2760866B1 (en) 2017-12-13
BR112014006924A2 (pt) 2017-04-11
CA2848518A1 (en) 2013-04-04
WO2013045519A1 (en) 2013-04-04
IL231501A0 (en) 2014-05-28
JP6042438B2 (ja) 2016-12-14
MX356683B (es) 2018-06-08
CN104024259B (zh) 2017-09-26
CN104024259A (zh) 2014-09-03
US9586963B2 (en) 2017-03-07

Similar Documents

Publication Publication Date Title
JP6042438B2 (ja) Ｒｅｖ−ｅｒｂアゴニストとしての６−置換トリアゾロピリダジン類の誘導体
RU2695337C2 (ru) ПРОИЗВОДНОЕ ПИРИДО[3,4-d]ПИРИМИДИНА И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМАЯ СОЛЬ
EP2509600B1 (en) Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
EP3750890B1 (en) Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof
CN109721527B (zh) 一种新型抗pd-l1化合物、其应用及含其的组合物
CN109071498A (zh) 激酶抑制剂及其制备方法和用途
KR20070009546A (ko) 단백질 키나제 의존성 질환의 치료에 사용하기 위한피라졸로[1,5-ａ]피리미딘-7-일-아민 유도체
SK4602002A3 (en) Pyrazolo [4,3-d]pyrimidine derivatives, method for producing thereof and their use
EP3135667A1 (en) Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
Elmasry et al. Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold
US20230339871A1 (en) Compounds and methods of modulating 17b-hydroxysteroid dehydrogenase type 13
US9138494B2 (en) Radiolabeled PDE10A ligands
CN117327057A (zh) 一类作为甲状腺激素受体激动剂的三嗪二酮类化合物及其合成、用途
CN107793371B (zh) 一类溴结构域识别蛋白抑制剂及其制备方法和用途
EP3715348A1 (en) Fused bicyclic compounds for the treatment of disease
TW202342457A (zh) 一種嗒𠯤酮衍生物製備方法及其中間物
HK1200448B (en) Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
US20060128707A1 (en) Imidazotriazinone derivatives as pde 7 (phosphodiesterase 7) inhibitors
JPH08176113A (ja) ２−スルフィニルニコチンアミド誘導体及びその中間体並びにそれを有効成分とする消化性潰瘍治療薬
CN120904203A (zh) Atr和parp1双靶点抑制剂
HK40049146A (en) Fused bicyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired